Consistently, a number of in vitro studies have shown that knockdown of NUCB2/nesfatin‐1 could inhibit the cell proliferation in breast cancer,22 bladder cancer,23 glioblastoma,9 endometrial cancer11 and thyroid cancer cell lines.12 Here, NUCB2 is linked to thyroid gland carcinoma.